Drug-Induced Liver Injury Clinical Trial
Official title:
A Randomized,Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MT2004 Capsule in Treatment of Cholestatic and Mixed Drug Induced Liver Injury (DILI)
The goal of this randomized, double-blind, placebo controlled, Multicenter Phase II clinical trial is to initially evaluate the Safety and Efficacy of MT2004 Capsule in Cholestatic and Mixed drug induced liver injury (DILI) subjects. The main questions it aims to answer are: 1. The Efficacy of MT2004 Capsule in Cholestatic and Mixed DILI subjects 2. The Safety and Pharmacokinetic characteristic of MT2004 Capsule in Cholestatic and Mixed DILI subjects 3. The mechanism of using MT2004 Capsule on Cholestatic and Mixed DILI subjects
Status | Recruiting |
Enrollment | 80 |
Est. completion date | October 10, 2025 |
Est. primary completion date | August 10, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - 1. 18= age = 75 years, male or female. 2. When diagnosis of acute DILI, the liver biochemical threshold of patients must meet one of the following criteria: :(1) ALT =5 ×ULN;(2) ALP =2× ULN;(3) ALT=3× ULN and TBil =2×ULN. 3. ALP =2× ULN, and conform to the clinical classification of cholestatic type or mixed type DILI in the Chinese Guidelines for the Diagnosis and Treatment of Drug-induced Liver Injury (2023 edition) (cholestatic type: R value =2; Mixed type: 2<R value <5). 4. Excluded other common causes of acute liver injury, such as acute viral hepatitis A, B, C, E, autoimmune hepatitis, biliary tract disease, PBC, etc. (Exclusive diagnostic tests completed in our hospital or other hospitals after this suspected acute DILI event or within 2 months before screening were acceptable) 5. RUCAM causality scale score =6 points; If the RUCAM score is between the 3-5 it is necessary to evaluate the causal relationship by three experts according to the evaluation criteria of expert opinions in the Chinese Guidelines for the Diagnosis and Treatment of Drug-induced Liver Injury (2023 edition), and at least two experts determine that the liver injury of the patients are "likely", "very likely" or "definitely" caused by drugs. 6. The serious level of DILI is within level 1-2 based on the Chinese Guidelines for the Diagnosis and Treatment of Drug-induced Liver Injury (2023 edition). 7. The duration of this liver injury is less than 6 months. 8. The female with fertility must have had a negative pregnancy test results before being enrolled, or at least 1 year after pausimenia, or permanent sterilization =6 weeks(There should have a recording of hysterectomy, bilateral salpingo-oophorectomy). The female and their male partners with the fertility potential agree to utilize the effective contraceptive methods(the following two methods can be selected: 1. any of the condom, diaphragm, Sponge or Cervical Cap with with Spermicide ). 9. Fully understand the study process of the clinical trial, and provide the signed ICF of joinning the clinical trial. Exclusion Criteria: - 1. Acute or chronic liver failure or liver decompensation 2. The history of liver decompensation or portal hypertension history 3. Moderate or above renal insufficiency, creatinine clearance (Ccr) < 60mL/min (according to the MDRD formula). 4. Patients with serious diabetes and had poor control of blood sugar (HbA1c>10%) 5. Serious sysmetic diseases of cardiovascular, respiratory, neurological, urinary, digestive, and for any reason which, in the opinion of the Investigator think the subject is not suitable for participating in the study. 6. The predict survival period < 6 months. 7. Utilization of Perursodeoxycholic acid within 14 days before the treatment. 8. Utilization of S-adenosylmethionine within 1 days before the treatment. 9. The patients must regularly utilize the known strong CYP3A4/3A5 inhibitors such as Clarithromycin, Itraconazole, ketoconazole, Ritonavir, rifampicin, phenytoin, carbamazepine within 1 week before the treatment or for the whole study period. 10. Allergies or intolerances to study drug ingredients 11. Patients are under the gestation, lactation, or patients have the pregnancy planning during the study period and 90 days after the end of the clinical trial 12. Patients are not willing to ban the alcohol during the study period. 13. Patients had joined the other clinical trials within 3 months before the administration. 14. Other conditions that the investigator think the subject is not suitable for participating in the study. |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Jiaotong University School of Medicine,Renji Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Xi'An Aolitai Pharmaceutical Technology Co Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Safety endpoint | Adverse Events(AEs) will be recorded and evaluated for their seriousness, severity, and relationship to the study drug. | From the date of screening until the date of last follow-up visit or early termination and end of study, assessed up to 12 weeks. | |
Primary | Primary efficacy endpoint | The efficacy of MT2004 will be evaluated based on the decreasing rate on serum ALP compared to baseline. | On the week 4 after the administration | |
Secondary | Secondary efficacy endpoint | The efficacy of MT2004 will be evaluated based on the decreasing rate on ALP compared to baseline. | On the week 2,8,12 after the administration and the week 4 follow-up period | |
Secondary | Secondary efficacy endpoint | The efficacy of MT2004 will be evaluated based on the percentage of patients whose ALP decreased by more than 15% from baseline. | On the week 2,4,8,12 after the administration and the week 4 follow-up period | |
Secondary | Secondary efficacy endpoint | The efficacy of MT2004 will be evaluated based on the recovery rate of ALP. | On the week 2,4,8,12 after the administration and the week 4 follow-up period | |
Secondary | Secondary efficacy endpoint | The efficacy of MT2004 will be evaluated based on the decreasing rate on GGT compared to baseline. | On the week 2,4,8,12 after the administration and the week 4 follow-up period | |
Secondary | Secondary efficacy endpoint | The efficacy of MT2004 will be evaluated based on the recovery rate of GGT. | On the week 2,4,8,12 after the administration and the week 4 follow-up period | |
Secondary | Secondary efficacy endpoint | The efficacy of MT2004 will be evaluated based on the decreasing rate on ALT compared to baseline. | On the week 2,4,8,12 after the administration and the week 4 follow-up period | |
Secondary | Secondary efficacy endpoint | The efficacy of MT2004 will be evaluated based on the recovery rate of ALT. | On the week 2,4,8,12 after the administration and the week 4 follow-up period | |
Secondary | Secondary efficacy endpoint | The efficacy of MT2004 will be evaluated based on the decreasing rate on AST compared to baseline. | On the week 2,4,8,12 after the administration and the week 4 follow-up period | |
Secondary | Secondary efficacy endpoint | The efficacy of MT2004 will be evaluated based on the recovery rate of AST. | On the week 2,4,8,12 after the administration and the week 4 follow-up period | |
Secondary | Secondary efficacy endpoint | The efficacy of MT2004 will be evaluated based on the decreasing rate on TBIL compared to baseline. | On the week 2,4,8,12 after the administration and the week 4 follow-up period | |
Secondary | Secondary efficacy endpoint | The efficacy of MT2004 will be evaluated based on the decreasing rate on TBA compared to baseline. | On the week 2,4,8,12 after the administration and the week 4 follow-up period | |
Secondary | Secondary efficacy endpoint | The efficacy of MT2004 will be evaluated based on the area of serum ALP decreasing rate-time curve. | On the week 2,4,8,12 after the administration | |
Secondary | Secondary efficacy endpoint | The efficacy of MT2004 will be evaluated based on the percentage of patients developed to DILI level 3-4 after the administration. | On the week 2,4,8,12 after the administration and the week 4 follow-up period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05517668 -
Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose
|
Phase 2 | |
Recruiting |
NCT05060289 -
A Prognostic Model for Drug-induced Liver Injury in China
|
||
Completed |
NCT03092817 -
Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)
|
Phase 3 | |
Completed |
NCT03211208 -
Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients
|
||
Not yet recruiting |
NCT02061826 -
Establishment of Drug-induced Liver Injury Databases and Application of Circulating microRNA(miRNA)
|
N/A | |
Completed |
NCT02182167 -
A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis
|
Phase 2/Phase 3 | |
Completed |
NCT03665402 -
A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status
|
N/A | |
Not yet recruiting |
NCT03091244 -
Surveillance for Early Liver Injuries Caused by Xianlin Gubao Capsule.
|
N/A | |
Not yet recruiting |
NCT03091218 -
Surveillance for Early Liver Injuries Caused by Runzao Zhiyang Capsule.
|
N/A | |
Not yet recruiting |
NCT03091556 -
Surveillance for Early Liver Injuries Caused by Xianlin Gubao Pill.
|
N/A | |
Not yet recruiting |
NCT03091608 -
Surveillance for Early Liver Injuries Caused by Xianlin Gubao Granule
|
N/A | |
Not yet recruiting |
NCT03060252 -
Surveillance for Early Liver Injuries Caused by Zhuanggu Guanjie Pill
|
N/A | |
Completed |
NCT02407964 -
A Retrospective Study on Drug Induced Liver Injury in China
|
N/A | |
Active, not recruiting |
NCT05144217 -
Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo
|
Phase 2/Phase 3 | |
Completed |
NCT01705041 -
Preliminary Evaluation of a Point-Of-Care Liver Function Test
|
N/A | |
Recruiting |
NCT02086708 -
Ultrasound Method to Measure Fibrosis of the Liver in Children
|
N/A | |
Recruiting |
NCT05465642 -
Alterations of Gut Microbiota and Serum Biochemical Markers in DILI Patients
|
||
Completed |
NCT01434173 -
Risk of Acute Liver Injury in Users of Antimicrobials
|
N/A | |
Completed |
NCT05532345 -
Discrimination of DILI and AIH by Artificial Intelligence
|
||
Completed |
NCT03602703 -
Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs
|